0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......


Basic View | Expanded View
 Showing 41-60 of 62 Articles
Original Investigation 
Georgios Tsivgoulis, MD; Ramin Zand, MD; Aristeidis H. Katsanos, MD; Guillaume Turc, PhD; Christian H. Nolte, MD; Simon Jung, MD; Charlotte Cordonnier, PhD; Jochen B. Fiebach, MD; Jan F. Scheitz, MD; Pascal P. Klinger-Gratz, MD; Catherine Oppenheim, PhD; Nitin Goyal, MD; Apostolos Safouris, MD; Heinrich P. Mattle, MD; Anne W. Alexandrov, PhD; Peter D. Schellinger, MD; Andrei V. Alexandrov, MD
Includes: Supplemental Content

Importance  Cerebral microbleeds (CMBs) have been established as an independent predictor of cerebral bleeding. There are contradictory data regarding the potential association of CMB burden with the risk of symptomatic intracerebral hemorrhage (sICH) in patients with acute ischemic stroke (AIS) treated with intravenous thrombolysis (IVT).

Objective  ...

Editorial: Cerebral Microbleeds and Thrombolysis; Mark Fisher, MD
Original Investigation 
Paul Geha, MD; Yang Yang, PhD; Mark Estacion, PhD; Betsy R. Schulman, PhD; Hajime Tokuno, MD; A. Vania Apkarian, PhD; Sulayman D. Dib-Hajj, PhD; Stephen G. Waxman, MD, PhD
Includes: Supplemental Content

Importance  There is a need for more effective pharmacotherapy for chronic pain, including pain in inherited erythromelalgia (IEM) in which gain-of-function mutations of sodium channel NaV1.7 make dorsal root ganglion (DRG) neurons hyperexcitable.

Objective  To determine whether pain in IEM can be attenuated via ...

Editorial: Understanding Atomic Interactions to Achieve Well-being; Juan M. Pascual, MD, PhD
Original Investigation 
Shannon L. Risacher, PhD; Brenna C. McDonald, PsyD, MBA; Eileen F. Tallman, BS; John D. West, MS; Martin R. Farlow, MD; Fredrick W. Unverzagt, PhD; Sujuan Gao, PhD; Malaz Boustani, MD, MPH; Paul K. Crane, MD, MPH; Ronald C. Petersen, MD, PhD; Clifford R. Jack Jr, MD; William J. Jagust, MD; Paul S. Aisen, MD; Michael W. Weiner, MD; Andrew J. Saykin, PsyD; for the Alzheimer’s Disease Neuroimaging Initiative
Includes: Supplemental Content

Importance  The use of anticholinergic (AC) medication is linked to cognitive impairment and an increased risk of dementia. To our knowledge, this is the first study to investigate the association between AC medication use and neuroimaging biomarkers of brain metabolism and atrophy as a proxy for understanding ...

Images in Neurology 
Saeed A. Alqahtani, MD; Richard Leigh, MD

This case report describes a woman in her 70s with a history of atrial fibrillation who presented with slurred speech and difficulty ambulating for 1 hour.

Comment & Response 
Brian P. Walcott, MD; Omar Choudhri, MD; Michael T. Lawton, MD

To the Editor Amin-Hanjani el al1 identified an important distinction in the natural history of atherosclerotic vertebrobasilar occlusive disease by separating the diagnosis of stenosis/occlusion with hemodynamic insufficiency. Could this be used to stratify patients more likely to benefit from intervention? Cautious optimism exists in the shadow ...

Comment & Response 
Fady T. Charbel, MD; Sepideh Amin-Hanjani, MD

In Reply We read with interest the letter by Walcott et al and thank them for their insightful comments. They note that whereas in carotid stenosis, artery-to-artery embolism is a common culprit, hypoperfusion as determined by the Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke ...

Editorial 
John T. Kissel, MD; A. Gordon Smith, MD

Sensory predominant peripheral neuropathy is a common disorder, affecting as many as 10% of individuals older than 40 years.1 Many of these patients have small fiber neuropathy (SFN). Despite 3 decades of intense study, SFN remains an enigmatic condition that is often difficult to diagnose and manage ...

Editorial 
Elizabeth C. Mormino, PhD; Kathryn V. Papp, PhD

In 2011, a National Institute on Aging−Alzheimer’s Association (NIA-AA) work group published criteria for classifying clinically normal older individuals into biomarker-defined stages of preclinical Alzheimer disease using measures of Aβ and neurodegeneration (ND).1 These staging criteria assume a trajectory that begins with aberrant Aβ accumulation, followed by ...

Original Investigation 
Mohammad A. Khoshnoodi, MD; Shaun Truelove, BA; Ahmet Burakgazi, MD; Ahmet Hoke, MD, PhD; Andrew L. Mammen, MD, PhD; Michael Polydefkis, MD, MHS
Includes: Supplemental Content

Importance  Few data are available on the natural history of small fiber neuropathy (SNF). Peripheral neuropathy typically follows a length-dependent pattern, leading us to hypothesize that patients with SFN would lose intraepidermal nerve fibers at the distal leg more quickly than at more proximal thigh sites.

Objective...

Editorial: Understanding Small Fiber Neuropathy; John T. Kissel, MD; A. Gordon Smith, MD
Original Investigation 
Eugenia Martinez-Hernandez, MD, PhD; Helena Ariño, MD; Andrew McKeon, MD; Takahiro Iizuka, MD; Maarten J. Titulaer, MD, PhD; Mateus M. Simabukuro, MD; Eric Lancaster, MD, PhD; Mar Petit-Pedrol, MS; Jesús Planagumà, PhD; Yolanda Blanco, MD, PhD; Robert J. Harvey, BSc, PhD; Albert Saiz, MD, PhD; Francesc Graus, MD, PhD; Josep Dalmau, MD, PhD
Includes: Supplemental Content

Importance  Symptoms of stiff-person syndrome (SPS), stiff-limb syndrome (SLS), or progressive encephalomyelitis with rigidity, myoclonus, or other symptoms (SPS-plus) can occur with several autoantibodies, but the relative frequency of each antibody, syndrome specificity, and prognostic implications are unclear.

Objective  To report the clinical and immunologic findings ...

Original Investigation 
Anja Soldan, PhD; Corinne Pettigrew, PhD; Qing Cai, MS; Mei-Cheng Wang, PhD; Abhay R. Moghekar, MBBS; Richard J. O’Brien, MD, PhD; Ola A. Selnes, PhD; Marilyn S. Albert, PhD; for the BIOCARD Research Team
Includes: Supplemental Content

Importance  Clinical trials testing treatments for Alzheimer disease (AD) are increasingly focused on cognitively normal individuals in the preclinical phase of the disease. To optimize observing a treatment effect, such trials need to enroll cognitively normal individuals likely to show cognitive decline over the duration of the ...

Editorial: Cognitive Decline in Preclinical Stage 2 Alzheimer Disease; Elizabeth C. Mormino, PhD; Kathryn V. Papp, PhD
JAMA Neurology Clinical Challenge 
Matthias Hoheisel, MD; Matthias Sturzenegger, MD; Niklaus Meier, MD

A 24-year-old woman had a strong unilateral headache located in her left cheek, eye, and forehead that evolved during the evening hours, peaked at night, and decreased again until the morning, without any remarkable trigger along with ipsilateral lacrimation, a red eye, and periorbital swelling but without ptosis. ...

Comment & Response 
Mohamed Y. Rady, BChir, MB(Cantab), MA, MD(Cantab); Joseph L. Verheijde, PhD, MBA, PT

To the Editor Greer et al1 analyzed compliance of hospital protocols on brain death (BD) determination with the 2010 American Academy of Neurology (AAN) guidelines. They posited that this neurologic standard is 100% accurate. We comment on the accuracy claim.

Comment & Response 
David M. Greer, MD, MA; Panayiotis N. Varelas, MD, PhD; Eelco F. M. Wijdicks, MD, PhD

In Reply Rady and Verheijde appear to have missed the point of our article1 or otherwise have chosen to use it as a platform to criticize the American Academy of Neurology Practice Parameters (AANPPs). Our study was designed to look at variability of US hospital policies in ...

Viewpoint 
Guy Helman, BS; Joshua L. Bonkowsky, MD, PhD; Adeline Vanderver, MD

This Viewpoint assesses the frequency of next-generation sequencing use among neurologists and identifies barriers in its implementation.

Editorial 
Daniel B. Drachman, MD

Come to me, come! New lamps for old!
I'm a Magician from No-One-Knows-Where.
Here are more lamps than my hands can hold,
Bright new lamps of copper and gold,
Full of smooth oil, with a soft and fair
Little flame that throws its beams to the sky.
I'll ...

Editorial 
Reinhard Hohlfeld, MD; Tania Kümpfel, MD

Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a surface molecule expressed by many types of immune cells, including T lymphocytes, B lymphocytes, monocytes, macrophages, and eosinophils.13 After intravenous infusion, the therapeutic antibody binds to CD52-expressing cells in blood and to a lesser ...

Editorial 
David Pleasure, MD

In this issue of JAMA Neurology, Cornett et al1 analyze clinical disability in 520 children and adolescents aged 3 to 20 years with Charcot-Marie-Tooth disease (CMT). Approximately half of the cohort had CMT type 1A (CMT1A), with the remainder distributed roughly equally between rarer forms of ...

Original Investigation 
Adam Bryant, MD; Harold Atkins, MD, FRCPC; C. Elizabeth Pringle, MD; David Allan, MD, MSc; Grizel Anstee, MD; Isabelle Bence-Bruckler, MD, FRCPC; Linda Hamelin, MScN; Michael Hodgins, MD; Harry Hopkins, RPh, FCSHP; Lothar Huebsch, MD, FRCPC; Sheryl McDiarmid, MBA; Mitchell Sabloff, MD, FRCPC; Dawn Sheppard, MD, MSc, FRCPC; Jason Tay, MD, MSc, FRCPC; Christopher Bredeson, MD, MSc, FRCPC
Includes: Supplemental Content

Importance  Some patients with myasthenia gravis (MG) do not respond to conventional treatment and have severe or life-threatening symptoms. Alternate and emerging therapies have not yet proved consistently or durably effective. Autologous hematopoietic stem cell transplant (HSCT) has been effective in treating other severe autoimmune neurologic conditions ...

Editorial: New Lymphs for Old; Daniel B. Drachman, MD
Original Investigation 
Kayla MD Cornett, BHK, MSc; Manoj P Menezes, MBBS, FRACP, PhD; Paula Bray, PhD; Mark Halaki, PhD; Rosemary R. Shy, MD; Sabrina W. Yum, MD; Timothy Estilow, OTR/L; Isabella Moroni, MD; Maria Foscan, PT; Emanuela Pagliano, MD; Davide Pareyson, MD; Matilde Laurá, MD, PhD; Trupti Bhandari, PT; Francesco Muntoni, MD, FRCPCH, FMed Sci; Mary M. Reilly, MD, FRCP; Richard S. Finkel, MD; Janet Sowden; Katy J. Eichinger, PT, DPT, NCS; David N. Herrmann, MBBCh; Michael E. Shy, MD; Joshua Burns, PhD; for the Inherited Neuropathies Consortium
Includes: Supplemental Content

Importance  Disease severity of childhood Charcot-Marie-Tooth disease (CMT) has not been extensively characterized, either within or between types of CMT to date.

Objective  To assess the variability of disease severity in a large cohort of children and adolescents with CMT.

Design, Setting, and Participants  A ...

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts